Credit Suisse’s DNA X Inc SONM Stock Holding History

Credit Suisse’s Portfolio SONM Stock Details SONM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-333	Closed	-$55K	–	4252
2021 Q4	$55K	Buy	+333	New	+$101K	﹤0.01%	4417

Other funds holding SONM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's SONM Position: Q1 2022 in Review

Credit Suisse sold out of DNA X Inc (SONM) in Q1 2022, closing a stake of 333 shares — an estimated $55K sold.

Credit Suisse first reported a position in SONM in Q4 2021 and held it in 1 quarter. The position peaked at $55K in Q4 2021. 13 funds tracked by Wall St. Rank hold SONM as of Q1 2022.

Credit Suisse reported no remaining DNA X Inc position as of Q1 2022 after selling out during the quarter.
Credit Suisse sold 333 DNA X Inc shares in Q1 2022, an estimated $55K.
Credit Suisse first reported a position in DNA X Inc in Q4 2021 and held it in 1 quarter.
Credit Suisse's DNA X Inc position peaked at $55K in Q4 2021.
13 funds tracked by Wall St. Rank held DNA X Inc as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.